Avita Medical (RCEL) Projected to Release Earnings on Thursday

Key Points

• Avita Medical is expected to report Q3 2026 results after market close on November 5, 2026. Analysts forecast a loss of $0.2394 per share and revenue of $22.35 million.
• The company beat expectations in its most recent quarter, reporting a $0.25 per-share loss versus the $0.29 consensus estimate and revenue of $21.70 million versus $20.25 million expected.
• Analyst sentiment is broadly positive, with five Buy, one Hold, and one Sell rating and a consensus price target of $12.20. Shares recently opened at $16.50, near their 52-week high of $16.68.

Avita Medical (NASDAQ:RCEL - Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Avita Medical to post earnings of ($0.2394) per share and revenue of $22.35 million for the quarter. Investors can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Avita Medical (NASDAQ:RCEL - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. The company had revenue of $21.70 million for the quarter, compared to analysts' expectations of $20.25 million. On average, analysts expect Avita Medical to post ($0.98) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Avita Medical Stock Performance

Avita Medical stock opened at $16.50 on Thursday. The firm's fifty day moving average price is $11.97 and its 200-day moving average price is $6.42. Avita Medical has a fifty-two week low of $3.22 and a fifty-two week high of $16.68. The stock has a market cap of $507.87 million, a P/E ratio of -11.46 and a beta of 1.99.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. BTIG Research raised their price target on Avita Medical from $11.00 to $15.00 and gave the company a "buy" rating in a report on Monday, October 12th. Lake Street Capital upped their price target on shares of Avita Medical from $8.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday, August 28th. TD Cowen increased their price objective on shares of Avita Medical from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, August 19th. Wall Street Zen raised shares of Avita Medical from a "sell" rating to a "hold" rating in a research report on Sunday, August 2nd. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Avita Medical in a report on Monday, September 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $12.20.

Avita Medical Company Profile

Avita Medical, Inc NASDAQ: RCEL is a regenerative medicine company focused on developing and commercializing therapies that use a patient's own cells to help restore damaged skin and tissue. Its lead product is the RECELL System, an autologous cell-harvesting device designed to prepare a suspension of a patient's skin cells at the point of care for application to wounds.

RECELL is used in the treatment of certain thermal burn wounds and other skin injuries. The system is intended to support wound healing and may reduce the amount of donor skin required for grafting by enabling clinicians to create a cell suspension from a small sample of the patient's healthy skin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.